Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with certain types of brain tumours called IDH wildtype gliomas, including diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma, or molecularly defined high-grade glioma or glioblastoma (GBM).
• People who have had a physical examination and health performance assessment (measuring how well a person can carry out daily activities) scored at 70 or above within the 30 days before enrolling.
• People who have had an MRI scan with contrast dye after surgery, which is required for radiation treatment planning.
• People for whom detailed MRI brain scans (specific thin-slice 3D and fluid-sensitive sequences) have been obtained for planning purposes — this is strongly encouraged but confirm details with the trial site.
• People whose recent blood test results (taken within 60 days before joining) show healthy enough levels of neutrophils (a type of white blood cell), platelets, and haemoglobin (red blood cell protein), including cases where a blood transfusion was used to reach the required haemoglobin level.
• People whose recent blood tests show liver function, kidney function, and waste-filtering levels within acceptable ranges (within 60 days before joining).

Who may not be able to join:

• People with clear clinical or scan-based evidence that their cancer has spread to other parts of the body.
• People with a history of another type of invasive cancer (other than certain non-melanoma skin cancers), unless there has been no sign of that cancer for at least 3 years — note that some early-stage (in situ) cancers of the breast, mouth, or cervix may still be acceptable (confirm with trial site).
• People who have previously had radiation treatment to the brain, head, or neck in a way that could overlap with the planned radiation area for this trial.
• People who have previously received chemotherapy or radiation therapy for any brain tumour.
• People whose brain tumour has been identified as gliosarcoma (WHO Grade IV) or pilocytic astrocytoma (WHO Grade I).
• People whose glioblastoma appears in multiple separate areas of the brain (known as multicentric glioblastoma).
• People whose cancer has spread to the membranes surrounding the brain and spinal cord (leptomeningeal disease).
• People who are unable to undergo MRI scans with and without contrast dye.
• People with serious, active health conditions, including any of the following:
  • Unstable chest pain or heart failure requiring hospitalisation in the 6 months before enrolling.
  • A heart attack within the last 6 months, or specific heart-related changes on a recent ECG (electrical heart test) taken within 28 days before joining (ECG only required if a heart problem is suspected).
  • A diagnosis of moderate-to-severe heart failure requiring hospitalisation within the 12 months before joining.
  • A serious, uncontrolled irregular heartbeat at the time of joining.
  • A serious or poorly healing wound, ulcer, bone fracture, or certain abdominal problems requiring major surgery or significant injury within 28 days before joining — except for the brain surgery related to this condition.
  • An active bacterial or fungal infection requiring intravenous antibiotics at the time of joining.
  • Serious liver disease causing yellowing of the skin or eyes (jaundice) or blood clotting problems.
  • A serious flare-up of a lung condition, or any breathing illness requiring hospitalisation or that would prevent participation in the trial at the time of joining.
  • HIV infection with a low immune cell count (CD4 below 200), or a diagnosis of AIDS — note that HIV testing is not required to join, but people with AIDS cannot participate due to the risk of serious complications from the immunosuppressive treatments involved.
• People with any other severely weakened immune system.
• People with active connective tissue diseases such as lupus or scleroderma, where the treating doctor considers radiation treatment to carry a high risk of serious side effects.
• People with end-stage kidney disease who are on dialysis or for whom dialysis has been recommended.
• People with other major physical health conditions or psychiatric conditions that, in the investigator's view, would prevent them from completing the trial treatment.

Important: Always verify eligibility with the trial site directly before applying.